CryoPort Inc Dossier
Financial Snapshot
Revenue, profitability, returns, debt, and capital allocation
Revenue $186.5M+18.9% YoYTTM through 30 Jun 2026
Net Income -$37.4MTTM through 30 Jun 2026
Free Cash Flow -$20MTTM through 30 Jun 2026
Margins
| Current | |
|---|---|
| Gross Margin | 47.1% |
| EBITDA Margin | -7.4% |
| Operating Margin | -20.9% |
| Net Margin | -20.1% |
Returns
15.6%ROE
10.2%ROA
Balance Sheet Health
Debt / Equity0.37x
Current Ratio2.17x
Net Debt-$225Mnet cash position
Cash & Equivalents$269.3M
Quality Metrics
Altman Z-Score1.15
Piotroski F-Score5 / 9
FCF Margin-10.7%
Rule of 40-6.5
Earnings-Beat Rate75.0%
Multi-Year Trend
RevenueFY2025: $176.2M
Diluted EPS-$0.90TTMFY2025: $1.56
Dividend
No dividend
Capital Allocation
R&D Spend$17.7M
Capex Intensity15.0%
Segment Performance
| Segment | Revenue | YoY | Outlook |
|---|---|---|---|
| Life Sciences Services | $96.5M | +18.0% | View detailsGrowth driven by expanding cell and gene therapy (CGT) activity and new BioServices operations in Paris (Q3 2026). |
| Life Sciences Products | $79.7M | +7.0% | View detailsSupported by the introduction of the new Fusion 800 Series. |
Filing Detail Members
This section is available to registered members. Create a free account or sign in to unlock the full breakdown.